Evaluation of HE4 , CA-125 , Risk of Ovarian Malignancy Algorithm ( ROMA ) and Risk of Malignancy Index ( RMI ) in the Preoperative Assessment of Patients with Adnexal Mass

• Published in: Oman medical journal Vol. 31; no. 5; pp. 336 - 344
• Main Authors: Al Musalhi , Khawla, Al Hatali , Khalsa, Al Rawahi , Thuraya, Mula-Abed , Waad-Allah, Ramadhan , Fatma, Al Aisary , Faiza, Al Kindi , Manal
• Format: Journal Article
• Language: English
• Published: Muscat - Oman Oman Medical Specialty Board 01.09.2016; OMJ
• Subjects: CA-125 Antigen; Cancer; Cancer in women; DIAGNOSIS; Human Epididymis-specific Protein E4; Original; OVARIAN DISEASES; OVARIAN NEOPLASMS; Ovaries; PATIENTS; Risk factors; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); SURGICAL OPERATIONS; أمراض المبيض; الأورام المبيضية; التشخيص; العمليات الجراحية; المرضى; Muscat; Oman; Human Epididymis-specific Protein E4; Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms; CA-125 Antigen; Risk of Malignancy Index (RMI)
• ISSN: 1999-768X; 2070-5204
• DOI: 10.5001/omj.2016.68

Objectives : To evaluate the validity and compare the performance of cancer antigen-125 (CA-125), human epididymis protein 4 (HE4), the risk of malignancy index (RMI), and the risk of ovarian malignancy algorithm (ROMA) in the diagnosis of ovarian cancer in patients with ovarian lesions discovered during their preoperative work-up investigations. Methods: This prospective, cross-sectional study looked at patients who attended the gynecology department at the Royal Hospital, Muscat, from 1 March 2014 to 30 April 2015, for the evaluation of an ovarian lesion. The inclusion criteria included women who underwent surgical intervention and who had a preoperative pelvic ultrasound with laboratory investigation for CA-125 and HE4. The study validated the diagnostic performance of CA-125, RMI, HE4, and ROMA using histopathological diagnosis as the gold standard. Results: The study population had a total of 213 cases of various types of benign (77%) and malignant (23%) ovarian tumors. CA-125 showed the highest sensitivity (79%) when looking at the total patient population. When divided by age, the sensitivity was 67% in premenopausal women. In postmenopausal women, CA-125 had lower sensitivity (89%) compared to RMI, HE4, and ROMA (93% each). A high specificity of 90% was found for HE4 in the total patient population, 93% in premenopausal women and 75% in postmenopausal women. CA-125 had the highest specificity (79%) in postmenopausal women. Both CA-125 and RMI were frequently elevated in benign gynecological conditions particularly in endometriosis when compared to HE4 and ROMA. We also studied modifications of the optimal cut-offs for the four parameters. Both CA-125 and RMI showed a significant increase in their specificity if the cut-off was increased to ≥ 60 U/mL for CA-125 and to ≥ 250 for RMI. For HE4, we noted an improvement in its specificity in postmenopausal women when its cut-off was increased to140 pmol/L. Conclusions: HE4 and ROMA showed a very high specificity, but were less sensitive than CA-125 and RMI in premenopausal women. However, they were of comparable sensitivity in postmenopausal women and were valuable in distinguishing benign ovarian tumors or endometriosis from ovarian cancer. Modifying the cut-off values of the different markers resulted in a higher accuracy compared to the standard cut-offs, but at the expense of reduced sensitivity